XSHG
600285
Market cap1.62bUSD
Oct 09, Last price
19.66CNY
1D
3.04%
1Q
-9.48%
Jan 2017
54.08%
IPO
220.20%
Name
Henan Lingrui Pharmaceutical Co Ltd
Chart & performance
P/E
14.68
P/S
2.89
EPS
1.34
Div yield, %
4.72%
Shrs. gr., 5y
-0.01%
Rev. gr., 5y
10.57%
Revenues
3.85b
+10.07%
Net income
760m
+5.11%
CFO
554m
-36.76%
Dividend
Jun 11, 20261.1 CNY/sh
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Established in 1992 and headquartered in Xinyang, China, Henan Lingrui Pharmaceutical Co., Ltd. specializes in the production and distribution of pharmaceutical products throughout the Chinese market. The company offers a broad catalog of approximately 100 different medications, provided in ten distinct dosage formats such as adhesive plasters, tablets, capsules, granules, and tinctures. Prominent items in their product line include Tongluoqutong plasters, Peiyuantongnao capsules, Danlutongdu tablets, stomachache free tablets, and Shenqi Hypoglycemic capsules.
Key people
Zirun Pan
Chief Financial Officer, Director · since 2023
Peng Yu
Chief Financial Officer · since 2020
Wei Xiong
Chairman of the Board, General Manager · since 2019
Lei Li
Deputy General Manager · since 2020
Xizhen Wu
Deputy General Manager, Director · since 2017
Qiang Ye
Deputy General Manager · since 2020
Guoxin Feng
Secretary of the Board, Director · since 2020
Yan Chen
Deputy General Manager, Director · since 2020
Hui Li
Independent Director · since 2020
Independent Director · since 2023
Qinyu Zhang
Independent Director · since 2024
Headquarters & legal address
河南省新县将军路666号
信阳市, HA 450000
CN
信阳市, HA 450000
CN
Valuation
Title CNY in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | ||||||||||
Revenues | ||||||||||
Cost of revenue | ||||||||||
Unusual Expense (Income) | ||||||||||
NOPBT | ||||||||||
NOPBT Margin | ||||||||||
Operating Taxes | ||||||||||
Tax Rate | ||||||||||
NOPAT | ||||||||||
Net income | ||||||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | ||||||||||
BB yield | ||||||||||
| Debt | ||||||||||
Debt current | ||||||||||
Long-term debt | ||||||||||
Deferred revenue | ||||||||||
Other long-term liabilities | ||||||||||
Net debt | ||||||||||
| Cash flow | ||||||||||
Cash from operating activities | ||||||||||
CAPEX | ||||||||||
Cash from investing activities | ||||||||||
Cash from financing activities | ||||||||||
FCF | ||||||||||
| Balance | ||||||||||
Cash | ||||||||||
Long term investments | ||||||||||
Excess cash | ||||||||||
Stockholders' equity | ||||||||||
Invested Capital | ||||||||||
ROIC | ||||||||||
ROCE | ||||||||||
| EV | ||||||||||
Common stock shares outstanding | ||||||||||
Price | ||||||||||
Market cap | ||||||||||
EV | ||||||||||
EBITDA | ||||||||||
EV/EBITDA | ||||||||||
Interest | ||||||||||
Interest/NOPBT | ||||||||||